Nuformix plc (LON:NFX – Get Free Report) reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as GBX 0.18 ($0.00) and last traded at GBX 0.18 ($0.00), with a volume of 1347616 shares changing hands. The stock had previously closed at GBX 0.21 ($0.00).
Nuformix Stock Performance
The company has a current ratio of 1.51, a quick ratio of 3.35 and a debt-to-equity ratio of 1.17. The firm has a 50-day moving average of GBX 0.22 and a 200-day moving average of GBX 0.27. The stock has a market capitalization of £1.64 million, a price-to-earnings ratio of -1.63 and a beta of 0.29.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
See Also
- Five stocks we like better than Nuformix
- What Is WallStreetBets and What Stocks Are They Targeting?
- Hasbro’s Management Made All the Right Calls This Quarter
- What Does a Stock Split Mean?
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- Trading Stocks: RSI and Why it’s Useful
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
